Status: Recruiting
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
Participants needed: 80
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Camille N. Kotton, MDUpdated: Dec 22, 2025Locations: 2
Eligibility criteria
High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kid... [+3]
Any pre-transplant CMV serologic combinations besides CMV D+/R- [+14]